Quarterly report [Sections 13 or 15(d)]

REVENUES

v3.26.1
REVENUES
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
REVENUES

NOTE 10 – REVENUES

Disaggregation of Net Revenues

The Company’s net product revenues are summarized below: 

 

               
    Three months ended
March 31,		  
    2026     2025  
TONMYA   $ 3,731     $ —  
Zembrace Symtouch     2,930       2,026  
Tosymra     217       403  
Total product revenues   $ 6,878     $ 2,429  

All sales are generated in the United States.

Gross-to-Net Sales Accruals

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

Our provision for gross-to-net allowances was $10.6 million at March 31, 2026, $1.9 million of which was recorded as a reduction to accounts receivable and $8.7 million recorded as a component of accrued expenses. The above allowances have been reduced by approximately $1.5 million related to adjustments in respect of prior years resulting in an additional $1.5 million of revenue being recognized during the three months ended March 31, 2026. Our provision for gross-to-net allowances was $5.1 million at March 31, 2025, $1.2 million of which was recorded as a reduction to accounts receivable and $3.9 million recorded as a component of accrued expenses.